Prescription medication · Orexin Receptor Antagonist
suvorexant
Also sold as Belsomra. Belsomra is used to treat insomnia in adults.
Data updated 2026-05-15
- 12,687
- FDA reportsModerately reported
- 15
- InteractionsSeveral interactions
- $14.19
- Brand price (NADAC)
What the data shows
suvorexant (Belsomra) is a prescription Orexin Receptor Antagonist, reported less often than most tracked drugs (12,687 FDA reports), with 15 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
suvorexant (Belsomra) is a prescription Orexin Receptor Antagonist. Belsomra is used to treat insomnia in adults.
Belsomra is a prescription medicine used to treat insomnia. It helps you fall asleep and stay asleep.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$14.19/unit
Generic Available
No
MERCK SHARP DOHME
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Belsomra is used to treat insomnia in adults.
Common side effects
Sleepiness
Key warnings
Belsomra can cause you to feel sleepy during the day and can impair your ability to drive.
The sections below are summarized in plain English from suvorexant's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Belsomra works by blocking orexin, a chemical in your brain that keeps you awake. By blocking orexin, Belsomra helps to reduce wakefulness and allows you to fall asleep.
Side Effects (from patient reports)
Based on 12,687 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for suvorexant, by number of reports
- Nightmare
Nightmare
736 reports
- Somnolence
Somnolence
726 reports
- Insomnia
Insomnia
674 reports
- Abnormal Dreams
Abnormal Dreams
599 reports
- Headache
Headache
535 reports
- Feeling Abnormal
Feeling Abnormal
485 reports
- Nausea
Nausea
381 reports
- Hallucination
Hallucination
372 reports
- Fatigue
Fatigue
353 reports
- Dizziness
Dizziness
325 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for suvorexant each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where suvorexant sits
suvorexant has more FDA adverse-event reports than 44% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is suvorexant; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 12,687 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2014–2025.
Total Reports
12,687
Reports Mentioning Death
686
5.4% of reports — not proof of cause
Hospitalization Reports
1,975
Top Indication
Insomnia
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | NIGHTMARE | 736 |
| 3 | SOMNOLENCE | 726 |
| 4 | INSOMNIA | 674 |
| 5 | ABNORMAL DREAMS | 599 |
| 6 | HEADACHE | 535 |
| 7 | FEELING ABNORMAL | 485 |
| 8 | NAUSEA | 381 |
| 9 | HALLUCINATION | 372 |
| 10 | FATIGUE | 353 |
| 12 | DIZZINESS | 325 |
| 13 | ANXIETY | 308 |
| 14 | FALL | 258 |
| 16 | MALAISE | 239 |
| 17 | DIARRHOEA | 237 |
| 20 | SLEEP PARALYSIS | 231 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Belsomra can cause you to feel sleepy during the day and can impair your ability to drive. Do not drive or do other activities that require you to be fully alert, especially if you take the 20 mg dose. Belsomra may also worsen depression or cause suicidal thoughts. Tell your doctor right away if you have any new or worsening mood changes. Complex sleep behaviors like sleepwalking have also been reported. Stop taking Belsomra and tell your doctor if this happens.
Known Drug Interactions
CYP3A Inhibitors Concomitant use of BELSOMRA with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) is not recommended [see Clinical Pharmacology (12.3) ].
Mechanism: Ketoconazole stops your body from breaking down suvorexant, which can lead to much higher levels of the sleep medicine in your blood. This can make you feel overly tired or cause other side effects.
CYP3A Inhibitors Concomitant use of BELSOMRA with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) is not recommended [see Clinical Pharmacology (12.3) ].
Mechanism: Clarithromycin blocks the enzyme that breaks down suvorexant, which can cause the sleep medicine to build up to high levels in your body.
CYP3A Inhibitors Concomitant use of BELSOMRA with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) is not recommended [see Clinical Pharmacology (12.3) ].
Mechanism: Posaconazole stops your body from clearing suvorexant, which can lead to higher levels of the sleep medicine in your system than intended.
Neuropsychiatric agents suvorexant ↑ suvorexant Avoid concomitant use of suvorexant with PAXLOVID.
Mechanism: Ritonavir slows down how quickly your body clears suvorexant, which can make the effects of the sleep medicine much stronger.
The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).
Mechanism: Diltiazem blocks the enzyme that breaks down suvorexant, which can cause the sleep medicine to build up in your body.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I drink alcohol while taking Belsomra?
Can I take Belsomra with other sleep medicines?
What should I do if I feel sleepy during the day?
Can Belsomra cause sleepwalking?
Is it okay to drive the day after taking Belsomra?
What if the 10mg dose isn't strong enough?
Can I take Belsomra if I have liver problems?
What if I am taking other medications?
Can Belsomra cause nightmares?
How long should I take Belsomra?
What are the common side effects of suvorexant?
Does suvorexant interact with other medications?
What drug class is suvorexant?
What pregnancy or breastfeeding source fields are listed for suvorexant?
Related Medications in Orexin Receptor Antagonist
Other drugs grouped near suvorexant - same-class peers and common alternatives.
eszopiclone
Lunesta
Eszopiclone (Lunesta) is a medicine that helps you fall asleep and stay asleep.
Compare with suvorexant →
lemborexant
Dayvigo
Dayvigo is a medicine that can help you fall asleep and stay asleep.
Compare with suvorexant →
melatonin
Melatonin
Melatonin is a hormone supplement that can help with sleep.
Compare with suvorexant →
ramelteon
Rozerem
Ramelteon (Rozerem) is a prescription medicine that can help you fall asleep faster.
Compare with suvorexant →
tasimelteon
Hetlioz
Tasimelteon (Hetlioz) is a medicine that helps people with Non-24-Hour Sleep-Wake Disorder (Non-24) sleep better.
Compare with suvorexant →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for suvorexant: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 12,687.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 5.41%.
- insulin degludec Δ 0.02 pts · 22,011 reports · Ultra-Long-Acting Insulin 5.42%death share
- brexpiprazole Δ 0.03 pts · 15,755 reports · Atypical Antipsychotic 5.43%death share
- brivaracetam Δ 0.10 pts · 4,286 reports · Anticonvulsant (SV2A Ligand) 5.51%death share
- ustekinumab Δ 0.12 pts · 98,899 reports · Anti-IL-12/23 Monoclonal Antibody 5.53%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on suvorexant
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for suvorexant
The FDA label for suvorexant (sold under brand names such as Belsomra) classifies it as a prescription-only medication in the Orexin Receptor Antagonist class. Belsomra is used to treat insomnia in adults. Official labeling lists 1 commonly reported side effect, including Sleepiness.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 12,687 voluntary reports. The database also lists 15 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: March 10, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages